The purpose of this study is to assess the impact of the KidneyIntelX assay utilized as part of the current standard of care on the management of patients seen in the primary care physician's office at Mount Sinai.
Study Type
OBSERVATIONAL
Enrollment
10,000
KidneyIntelX is an in-vitro diagnostic that enables accurate risk prediction of progressive decline in kidney function in patients with type 2 diabetes and existing CKD at stages 1-3 (eGFR of 30 to 59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 and uACR ≥ 30 mg/g).
Mount Sinai Health System
New York, New York, United States
RECRUITINGReferrals
Proportion (target: 20%) of patients referred to a dietician, diabetologist, or nephrologist.
Time frame: 6 Months
Statins and or ACEi/ARB
Proportion (target: 20% increase) of patients treated with statins and or angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers.
Time frame: 6 Months
HbA1c
Proportion (target: 20% increase) of patients to receive information and or advice on their individualized target of HbA1c.
Time frame: 6 Months
SGLT2/ GLP1
Proportion (target: 20% increase) of patients treated with SGLT2 inhibitors or GLP1 agonists.
Time frame: 6 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.